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Sir,
Acinetobacter baumannii is one of the most common organisms
causing healthcare-associated infections in hospitals, especially
within intensivecareunits (ICUs). Carbapenemresistance inA.bau-
mannii is most often mediated by acquired class D carbapenem-
hydrolysing b-lactamases and in particular OXA-23.1 Recently,
the emergence of Ambler class A GES-type carbapenemases in
A. baumannii has been demonstrated, being identiﬁed in France,
Belgium and Kuwait.2–4
Theaimof our studywas to analyse themolecular epidemiology
and clinical features of carbapenem-resistant A. baumannii (CRAB)
clinical isolates recovered in a Turkish hospital. Isolates were recov-
ered from patients hospitalized in two ICUs (respiratory and anaes-
thesiology) at the 2000 bed Ege University Medical School Hospital
located in I˙zmir, western Turkey, from1March to 1 September 2012
(a 6 month period). The total number of patients in the two ICUs
over the study period was 318. The total number of patient days
(length of stay×patient number) was 5935.
The CRAB isolates were recovered from clinical specimens of
patients diagnosed with ventilator-associated pneumonia (VAP)
and/or bacteraemia. Patientswhowere colonizedwithA. bauman-
nii, butwithout anysign of infection,were excluded from the study.
A total of 60 patients (24 females and 36 males; mean age
64+2 years) were included in the study. The 60 CRAB isolates
were identiﬁed by incubation at 448Cand byusing the Vitek 2 iden-
tiﬁcation system (bioMe´rieux, La Balme-les-Grottes, France). They
were then furtherconﬁrmedbyspeciﬁcPCR targeting theblaOXA-51-
like genes intrinsic to A. baumannii.2 The mean APACHE II score
of the patients was 19+7.2. Forty-ﬁve patients (75%) had VAP
and 15 (25%) had bacteraemia. None of these patients had
received an appropriate empirical antimicrobial therapy. Fifteen
(10 bacteraemia and 5 VAP) patients died before having being
treated with an appropriate antimicrobial therapy within the ﬁrst
48 h (mortality rate 100%). The overall crude mortality rate for
the 45 patients for whom the antimicrobial treatment was
appropriate was 55.6% (P,0.001). The antibiotic regimens were
mostly combinations, being either colistin/tigecycline (n¼20),
colistin/netilmicin (n¼12), colistin/meropenem (n¼3), tigecycline/
meropenem (n¼6) or colistin monotherapy (n¼4) (Table 1).
Antibiotic susceptibility was determined by disc diffusion and
MICs of tigecycline, colistin, imipenemandmeropenemwere deter-
mined by using Etest strips (AB bioMe´rieux, La Balme-les-Grottes,
France) and interpreted according to the updated CLSI guidelines
when applicable.5 All of the 60 isolates were resistant to all
b-lactams, including broad-spectrumcephalosporins and carbape-
nems,and toﬂuoroquinolones. Resistance rates toamikacin, genta-
micin and netilmicin were 73%, 65% and 36%, respectively. In
addition, 33% of the isolates were resistant to all aminoglycosides
tested. Four isolates showed reduced susceptibility to tigecycline
(MICs of 1 mg/L) and ﬁve isolates were highly resistant (MICs of
3 mg/L). All of the isolates remained susceptible to colistin.
Identiﬁcation of carbapenemase and class A extended-
spectrum b-lactamase (ESBL) genes was performed by PCR and
sequencing,2–4 showing that the 60 isolates were all positive for
the blaOXA-23 carbapenemase gene. In addition, ﬁve isolates were
positive for the blaGES-11 gene, encoding an ESBL possessing a
weak carbapenemase activity.6 PCR mapping identiﬁed the
aacA4 gene cassette encoding the AAC(6′)-Ib aminoglycoside
acetyltransferase together with the dfrA7 gene cassette encoding
resistance to trimethoprim downstream of blaGES-11.
In order to determine the genetic location of carbapenemase-
or ESBL-encoding genes, conjugation assays were performed
using A. baumannii BM4547 (rifampicin resistant) as the recipient
strain, as described previously.2 Mating-out assays allowed A. bau-
mannii BM4547 transconjugants harbouring the blaGES-11 gene to
be obtained. Those A. baumannii transconjugants expressed both
OXA-23 and GES-11 and the corresponding blaGES-11 and
blaOXA-23 genes were identiﬁed on a single 100 kb plasmid. The
transconjugants showed resistance toallb-lactams, including car-
bapenems and aminoglycosides. Plasmid typing performed by
A. baumannii PCR-based replicon typing7 identiﬁed the 100 kb
plasmid as belonging to group 6, carrying the two carbapenemase
genes in all transconjugants.
Genotypic analysis of the 60 clinical isolates was performed by
PFGE and allowed them to be grouped into ﬁve distinct pulsotypes
(data not shown). This grouping was further conﬁrmed by using
the Diversilab technique (bioMe´rieux), which indicated that the
ﬁve GES-11-positive isolates belonged to three different clonal
lineages, with three isolates belonging to a single clone (data not
shown). Multilocus sequence typing performed as described previ-
ously8 on the ﬁve GES-11-positive A. baumannii isolates revealed
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that they all belonged to ST2, being part of the worldwide-
distributed clone II group.
The current emergence of CRAB is a signiﬁcant source of
concern worldwide. Strains producing the carbapenemases
OXA-58 and OXA-23 have been previously identiﬁed in Turkey.
Here, only OXA-23 producers were identiﬁed, despite the fact
that ﬁve clones were concomitantly identiﬁed in this hospital.
The clonal diversity identiﬁed here revealed a polyclonal outbreak
situation in the ICUs during that period of time. As previously
reported, the overall mortality of the patients infected with those
CRABs was very high, especially when they did not receive
adequate empirical therapy. According to the resistance proﬁle of
the studied isolates, colistin was the most effective antimicrobial.
While our work was in progress, another study reported the
occurrence of GES-11 and GES-12 enzymes among A. baumannii
isolates in Turkey.9 This highlights the need for implementation of
adequate screening techniques to identify patients colonized by
those multidrug-resistant strains.
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Table 1. Clinical characteristics of patients infected by the GES-producing A. baumannii isolates
Age
(years) Gender Comorbidity Infection
APACHE II
score
Length of
stay in ICUa
Empirical
treatment Treatment after culture Outcome
48 female connective tissue disorder VAP 21 9 meropenem tigecycline+colistin death
67 male solid organ tumour+abdominal
surgery
VAP 32 14 meropenem netilmicin+colistin death
83 male multiple trauma VAP+bacteraemia 11 5 meropenem — death
79 male solid organ tumour bacteraemia 10 5 levoﬂoxacin tigecycline+meropenem survival
49 female solid organ tumour+abdominal
surgery
bacteraemia 15 14 ceftriaxone tigecycline+netilmicin survival
aNumber of days before isolation of A. baumannii.
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